Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 20/20 | 0.67 |
| ▸ | CYBB | P04839 | 8/20 | 0.60 |
| ▸ | NOX1 | Q9Y5S8 | 8/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | NOX5 | Q96PH1 | 7/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523167 | 1.00 | NOX4 (0.67) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL29523426 | 0.91 | NOX4 (0.64) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL14931771 | 0.91 | NOX4 (0.64) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL14931744 | 0.89 | NOX4 (0.56) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL29522947 | 0.89 | NOX4 (0.56) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL14931738 | 0.86 | NOX4 (0.61) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL29522956 | 0.86 | NOX4 (0.61) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL29523001 | 0.86 | NOX4 (0.63) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL14931608 | 0.86 | NOX4 (0.63) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL18942605 | 0.82 | NOX4 (0.54) | NOX4CYBBNOX1CYP3A4NOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111971284-A | COMBINATION MODES OF NUCLEOSIDE AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELLIS-SPECIFIC ANTIVIRAL AGENTS | 埃默里大学 | 2020-11-20 | — | — | CN | claimed |
| EP-2776027-B1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | GENKYOTEX SUISSE SA (CH) | 2017-06-07 | — | — | EP | claimed |
| WO-2015049655-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF PDE5 INHIBITOR-POORLY RESPONSIVE ERECTILE DYSFUNCTION | GENKYOTEX SA (CH) | 2015-04-09 | — | — | WO | claimed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | claimed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | claimed |
| CN-114026067-A | Peptide mimetics for the treatment of coronavirus and picornavirus infections | 埃默里大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-111971284-A | COMBINATION MODES OF NUCLEOSIDE AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELLIS-SPECIFIC ANTIVIRAL AGENTS | 埃默里大学 | 2020-11-20 | — | — | CN | disclosed |
| EP-2776027-B1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | GENKYOTEX SUISSE SA (CH) | 2017-06-07 | — | — | EP | disclosed |
| WO-2015049655-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF PDE5 INHIBITOR-POORLY RESPONSIVE ERECTILE DYSFUNCTION | GENKYOTEX SA (CH) | 2015-04-09 | — | — | WO | disclosed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | Johann Wolfgang Goethe-Universität (DE) | 2014-10-30 | — | — | US | disclosed |
| EP-2591782-A1 | Nadph oxidase 4 inhibitors and use thereof | Johann Wolfgang Goethe-Universität (DE) | 2013-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323500-A1 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF | NOX4, NOX1, NOX5 | NOX4 1/4885CYBB 6/4885NOX1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.